8-K: Invivyd Reports $2.3 Million in Q2 Revenue, Advances Pipeline Amidst COVID-19 Evolution

Invivyd launched PEMGARDA commercially in Q2 2024, generating $2.3 million in net product revenue and is preparing for the upcoming respiratory virus season.

Summary

• Invivyd reported $2.3 million in net product revenue for the second quarter of 2024 following the commercial launch of PEMGARDA.
• The company ended the quarter with $147.9 million in cash and cash equivalents.
• Invivyd is maintaining its 2024 revenue guidance of $150 million to $200 million and expects to end the year with at least $75 million in cash.
• Research and development expenses were $30.3 million for the quarter, a decrease from $43.8 million in the same period last year.
• Selling, general, and administrative expenses increased to $21.1 million, up from $10.1 million in the prior year, due to commercial launch activities.
• The net loss for the quarter was $47.2 million, compared to $50.2 million in the same quarter of 2023.
• Invivyd is preparing for the fall/winter respiratory virus season, aiming to increase PEMGARDA awareness and utilization.
• The company plans to initiate a first-in-human clinical trial for its next-generation antibody, VYD2311, in late August.
• Invivyd has submitted an Emergency Use Authorization (EUA) amendment request to the FDA for PEMGARDA to treat mild-to-moderate COVID-19 in certain immunocompromised patients.
• The company has expanded its commercial team and added new independent directors to its board.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with the commercial launch of PEMGARDA and the advancement of the pipeline, but there are some concerns about the net loss and the need for additional capital. The company is making progress but faces challenges.

Positives

• PEMGARDA's commercial launch has resulted in $2.3 million in net product revenue in the second quarter of 2024.
• The company has a strong cash position of $147.9 million at the end of Q2 2024.
• Invivyd is on track to meet its 2024 revenue guidance of $150 million to $200 million.
• The company is advancing its pipeline with the first-in-human trial of VYD2311 scheduled for late August.
• Invivyd has achieved Medicare and Medicaid coverage for PEMGARDA.
• There has been rapid growth in commercial coverage across national and regional plans.
• The company has expanded its commercial leadership team and board of directors.
• Invivyd has seen a doubling of available infusion sites from the end of May to the end of June, and again from the end of June to the end of last week.
• The company has aligned with the FDA on an immunobridging pathway for future potential EUAs for novel mAbs.
• Invivyd has demonstrated continued in vitro neutralization activity of VYD222 and VYD2311 against emerging SARS-CoV-2 variants.

Negatives

• The company experienced a net loss of $47.2 million for the quarter ended June 30, 2024.
• Selling, general, and administrative expenses increased significantly to $21.1 million due to the PEMGARDA launch.
• A potential vendor contamination event requires regeneration of one AVNA value, which may impact the PEMGARDA fact sheet.
• The company is still reliant on third parties for manufacturing, labeling, packaging, storing and distributing clinical and commercial supplies of its product candidates.
• The company is continuing to evaluate multiple sources of additional capital.

Risks

• The EUA for PEMGARDA could be revoked or revised by the FDA.
• The company's ability to maintain and expand sales, marketing, and distribution capabilities is crucial for PEMGARDA's success.
• Changes in competition could impact the company's market position.
• The outcome of the EUA amendment request for PEMGARDA for treatment of mild-to-moderate COVID-19 is uncertain.
• There are risks associated with the regulatory authorization or approval process.
• Unexpected safety or efficacy data from clinical trials could impact the company's product candidates.
• The company is dependent on third parties for various aspects of its operations.
• There is a risk that the company may not be able to obtain and maintain third-party coverage and adequate reimbursement for PEMGARDA.
• The company's ability to continue as a going concern is dependent on securing additional funding.
• The company is subject to legal proceedings or investigations.

Future Outlook

Invivyd anticipates $150 million to $200 million in net product revenue for 2024 and expects to end the year with at least $75 million in cash. The company is also focused on advancing its pipeline, particularly VYD2311, and expanding the commercial reach of PEMGARDA.

Management Comments

• Marc Elia, Chairperson of the Invivyd Board of Directors, stated that early revenues reflect just the beginning of a unique, fast-growing, medically critical prophylactic category in infectious disease.
• Tim Lee, Chief Commercial Officer of Invivyd, expressed excitement about the positive commercial momentum and the company's efforts to drive awareness of PEMGARDA.

Industry Context

The announcement comes as the biopharmaceutical industry continues to grapple with the ongoing COVID-19 pandemic and the need for effective treatments and preventative measures, particularly for vulnerable populations. Invivyd's focus on monoclonal antibodies aligns with the industry's broader efforts to develop targeted therapies for infectious diseases.

Comparison to Industry Standards

• Invivyd's $2.3 million in net product revenue in the first quarter of commercialization is a modest start compared to established pharmaceutical companies, but is a positive sign for a newly launched product.
• The company's R&D spending of $30.3 million is typical for a biotech company in the clinical development phase, but is lower than the previous year.
• The increase in SG&A expenses to $21.1 million reflects the costs associated with launching a new product, which is a common trend in the industry.
• The company's cash position of $147.9 million is adequate for its current operations, but the need to evaluate multiple sources of additional capital suggests that further funding may be required.
• The company's focus on next-generation mAbs like VYD2311 is consistent with the industry's push for more potent and versatile therapies.

Management Changes

Related Party Transactions

• Research and development expenses include related-party amounts of $1,131 and $2,266 for the three and six months ended June 30, 2024, respectively.

Stakeholder Impact

• Shareholders may be encouraged by the initial revenue from PEMGARDA and the progress of the pipeline, but concerned about the net loss and the need for additional capital.
• Employees may be impacted by the company's growth and the expansion of the commercial team.
• Healthcare professionals will have a new treatment option for immunocompromised patients.
• Patients will benefit from the availability of PEMGARDA for COVID-19 prevention and potentially treatment.
• Suppliers and creditors may be impacted by the company's financial performance and future funding needs.

Next Steps

• Initiate first-in-human clinical trial for VYD2311 in late August.
• Continue commercialization efforts for PEMGARDA, focusing on the upcoming respiratory virus season.
• Submit EUA amendment request to the FDA for PEMGARDA to treat mild-to-moderate COVID-19.
• Continue to evaluate multiple sources of additional capital.
• Release CANOPY 180-day data.

Key Dates

Keywords

PEMGARDA, COVID-19, monoclonal antibody, EUA, immunocompromised, VYD2311, commercial launch, respiratory virus, FDA, clinical trial, net product revenue, immunobridging, mAbs